共 50 条
Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease
被引:41
|作者:
Cales, Paul
[1
,2
]
Boursier, Jerome
[1
,2
]
Chaigneau, Julien
[2
]
Laine, Fabrice
[3
,4
]
Sandrini, Jeremy
[5
]
Michalak, Sophie
[2
,5
]
Hubert, Isabelle
[1
,2
]
Dib, Nina
[1
,2
]
Oberti, Frederic
[1
,2
]
Bertrais, Sandrine
[2
]
Hunault, Gilles
[2
]
Cavaro-Menard, Christine
[6
]
Gallois, Yves
[7
]
Deugnier, Yves
[3
,4
]
Rousselet, Marie C.
[2
,5
]
机构:
[1] CHU Angers, Serv Hepatogastroenterol, F-49933 Angers 09, France
[2] Univ Angers, PRES UNAM, Lab HIFIH, Angers, France
[3] CHU, Hop Pontchaillou, INSERM, CIC 0203, Rennes, France
[4] CHU, Hop Pontchaillou, Serv Malad Foie, Rennes, France
[5] CHU Angers, Dept Pathol Cellulaire & Tissulaire, F-49933 Angers 09, France
[6] Univ Angers, PRES UNAM, Lab Ingn Syst Automatises, Angers, France
[7] CHU Angers, Lab Biochim & Biol Mol, F-49933 Angers 09, France
关键词:
area of fibrosis;
blood test;
fractal dimension;
image analysis;
liver biopsy;
liver fibrosis;
metabolic syndrome NAFLD;
LOGISTIC-REGRESSION;
IMAGE-ANALYSIS;
ACCURACY;
MODELS;
VARIABILITY;
VALIDATION;
BIOPSY;
SYSTEM;
NAFLD;
D O I:
10.1111/j.1478-3231.2010.02314.x
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Aims: Our aim was to develop an accurate, non-invasive, blood-test-based method for identifying the main characteristics of liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Methods: Fibrosis was staged according to NASH-CRN and Metavir systems in 226 patients with NAFLD. A fully automated algorithm measured the fractal dimension (FD) and the area of fibrosis (AOF). Independent predictors of diagnostic targets were determined using bootstrap methods. Results: (i) Development. Significant fibrosis defined by NASH-CRN F >= 2 was diagnosed by weight, glycaemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and prothrombin index [area under the receiver operating characteristic (AUROC) = 0.867]; significant fibrosis defined by Metavir F >= 2 was diagnosed by weight, age, glycaemia, AST, ALT, ferritin and platelets (FibroMeter AUROC = 0.941, P < 0.005). AOF was estimated by the combination of hyaluronic acid, glycaemia, AST, ALT, platelets and prothrombin index (R-a(2) = 0.530), while FD was estimated by hyaluronic acid, glycaemia, AST/ALT, weight and platelets (R-a(2) = 0.529). (ii) Evaluation. Although NASH-CRN was a better system for fibrosis staging, Metavir staging was a better reference for blood test. Thus, the patient rate with predictive values >= 90% by tests was 97.3% with Metavir reference vs. 66.5% with NASH-CRN reference (P < 10(-3)). FibroMeter showed a significantly higher AUROC than the NAFLD fibrosis score for significant fibrosis, but not for severe fibrosis or cirrhosis, with both staging systems. Relationships between fibrosis lesions were well reflected by blood tests, e. g., the correlation between histological area and FD of fibrosis (r(s) = 0.971, P < 10(-3)) was well reflected by the relationship between respective blood tests (rs = 0.852, P < 10(-3)). Conclusions: Different characteristics of fibrosis in NAFLD can be diagnosed and quantified by blood tests with excellent accuracy.
引用
收藏
页码:1346 / 1354
页数:9
相关论文